| 02/03 | Lilly to Participate in Guggenheim Oncology Conference | PR |
| 02/02 | HighTide Therapeutics Appoints Dr. Tianwei Ma as VP of Discovery Research | AQ |
| 02/02 | Eli Lilly And : Q4 2022 Financial Workbook | PU |
| 02/02 | Lilly : Q4 Earnings Snapshot | AQ |
| 02/02 | Eli Lilly And : Q4 2022 Lilly Press Release | PU |
| 02/02 | Eli Lilly And : Q4 2022 Lilly Presentation | PU |
| 02/02 | Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline .. | PR |
| 01/27 | U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Rev.. | PR |
| 01/26 | Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold .. | PR |
| 01/24 | Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangl.. | PR |
| 01/19 | U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Appro.. | PR |
| 01/19 | Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Annou.. | PR |
| 01/11 | Eli Lilly And : Estimated acquired ipr&d and development milestone charges | PU |
| 01/11 | University Of Hawai'i : National award to advance peptide drug development | AQ |
| 01/04 | Lilly to Participate in the J.P. Morgan Healthcare Conference | PR |
| 2022 | Lilly and ProQR to Expand RNA Editing CollaborationNew agreement supports the discovery.. | AQ |
| 2022 | Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY in Co.. | AQ |
| 2022 | Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diab.. | AQ |
| 2022 | Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable.. | AQ |
| 2022 | Lotus acquires Alimta in Taiwan from Lilly | AQ |
| 2022 | Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable.. | PR |
| 2022 | Eli Lilly And : 2023 Guidance Presentation | PU |
| 2022 | Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines | PR |
| 2022 | Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend | PR |
| 2022 | Boehringer Ingelheim - Phase III trial demonstrated Jardiance is the first SGLT2 inhibi.. | AQ |
| 2022 | Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistica.. | PR |
| 2022 | Chronic Lower Back Pain Pipeline Offers Novel Treatment Options | 10+ Companies & 10+ D.. | AQ |
| 2022 | Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Dis.. | PR |
| 2022 | Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptoma.. | PR |
| 2022 | Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement | PR |
| 2022 | Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium | PR |
| 2022 | Lilly to Participate in Evercore ISI HealthCONx Conference | PR |
| 2022 | Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform | PR |
| 2022 | Akouos Investor Alert By The Former : Kahn Swick & Foti, LLC Investigates Adequacy of Pri.. | PR |
| 2022 | ELI LILLY & CO Management's Discussion and Analysis of Results of Operations and
Finan.. | AQ |
| 2022 | Eli Lilly And : Q3 2022 Lilly Presentation | PU |
| 2022 | Lilly : Q3 Earnings Snapshot | AQ |
| 2022 | Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progres.. | PR |
| 2022 | Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufac.. | PR |
| 2022 | Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announ.. | PR |
| 2022 | Lilly Declares Fourth-Quarter 2022 Dividend | PR |
| 2022 | Eli Lilly & Co : Other Events (form 8-K) | AQ |
| 2022 | Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adu.. | PR |
| 2022 | FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adu.. | PR |
| 2022 | Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to R.. | AQ |
| 2022 | Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase .. | PR |
| 2022 | Lilly Announces Details of Presentations at ESMO Congress 2022 | PR |
| 2022 | Eli Lilly And : 2022 CDP Climate Change Report | PU |
| 2022 | Eli Lilly And : 2022 CDP Water Security Report | PU |
| 2022 | Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference | PR |
| 2022 | Lilly to Participate in Citi's 17th Annual BioPharma Conference | PR |
| 2022 | Direct Relief Delivers Seven-Week Supply of Long-Acting Insulin to Ukraine, Donated by .. | AQ |
| 2022 | Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Offic.. | PR |
| 2022 | Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs | AQ |
| 2022 | Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce In.. | PR |
| 2022 | Biden team, Eli Lilly condemn new Indiana abortion ban | AQ |
| 2022 | ELI LILLY & CO Management's Discussion and Analysis of Results of Operations and
Finan.. | AQ |
| 2022 | Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results | PR |
| 2022 | Eli Lilly And : Q2 2022 Financial Workbook | PU |
| 2022 | Eli Lilly And : Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New.. | PU |
| 2022 | Eli Lilly And : Q2 2022 Lilly Press Release | PU |
| 2022 | Lilly : Q2 Earnings Snapshot | AQ |
| 2022 | Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines an.. | PR |
| 2022 | Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Annou.. | PR |
| 2022 | Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ong.. | PR |
| 2022 | Lilly Declares Third-Quarter 2022 Dividend | PR |
| 2022 | Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs | AQ |
| 2022 | Eli Lilly And : Lilly Diabetes & Obesity ADA Update Presentation | PU |
| 2022 | Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab.. | PR |
| 2022 | Lilly to Participate in Goldman Sachs Global Healthcare Conference | PR |
| 2022 | Lilly to build two new US manufacturing sites | AQ |
| 2022 | Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana | PR |
| 2022 | Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Cli.. | PR |
| 2022 | Lilly to Participate in UBS Global Healthcare Conference 2022 | PR |
| 2022 | Eli Lilly & Co : Change in Directors or Principal Officers, Financial Statements and Exhib.. | AQ |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
